Aerase, Inc.

Immedica Pharma Ab

Scott W Rowlinson

Anthony G Quinn

David Lowe

Susan Alters

Ann Lowe

Giulia Agnello

Andreas Schulze

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.

Methods for production of human recombinant arginase 1 and uses thereof

Methods and compositions therefor of treating GAMT deficiency or guanidino acetate (GAA) toxicity in a subject comprising administration of an arginine depleting enzyme. An therapeutic formulation can include an arginase, an arginine deiminase or a combination thereof and optionally other compounds, and can be adapted for intravenous or subcutaneous administration to a subject.

Arginine depletion therapy for treatment of GAMT deficiency

A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.

Method and composition for treating arginase 1 deficiency

Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.

Growing community of inventors

Austin, TX, United States of America

Scott W Rowlinson